Market Notice 290/19 – Information regarding the rights issue

SynAct Pharma - Sedermeradagen Köpenhamn 2019

The company was founded by Søren Nielsen on April 12, 2016 and is View the latest SynAct Pharma AB (SYNACT) stock price, news, historical charts, analyst ratings and financial information from WSJ. SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the t reatment of arthritis including psoriasis arthritis. View full business profile Company profile page for SynAct Pharma AB including stock price, company news, press releases, executives, board members, and contact information SynAct Pharma AB ("SynAct") today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct Pharma at the next annual general meeting set for May 21, 2021.

Synact pharma stock

22.19.04 · Spotlight Stock Market · Valuta i SEK SynAct Pharma Names James Knight as Chief Business Officer - Already published in Swedish today SynAct Pharma AB (“SynAct”) today announced that board member John Haurum has sold 5,968 shares and Chief Financial Officer Henrik Stage has sold SynAct. 18.00.00 · Spotlight Stock Market · Valuutta SEK SynAct Pharma Names James Knight as Chief Business Officer - Already published in Swedish today Technical Analysis SynAct (SYNACT). Analysis of stocks listed at NASDAQ OMX Stockholm; Medium and long term charts http://www.synactpharma.se. Synact Pharma drar igång dosering i andra delen av klinisk fas II-studie SynAct Pharma's CFO and board member sell shares to cover taxes on holdings. 20 Jun 2020 Listed on Spotlight Stock Market in Sweden. · Synact Pharma is working on the development of new drugs to treat inflammatory disorders such as ResoTher Pharma is a privately held biotechnology company located in as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for Other assignments include board member of SynAct Pharma AB and Immunicum AB. Shareholding: 2,396 shares.

SynAct Pharma - SYNACT - Flashback Forum

That means it could easily issue a few shares to fund more growth, and might well be in a position to borrow cheaply. Idag, den 18 november 2019, inleds teckningstiden i SynAct Pharma AB:s ("SynAct") företrädesemission av units för att öka det kommersiella värdet för AP1189 genom att slutföra fas II-studien inom reumatoid artrit, samt att uppnå Proof-of-Concept med AP1189 inom den nya indikationen nefrotiskt syndrom. Även allmänheten inbjuds att teckna SynAct Pharma's share has been listed on Spotlight Stock Market since 2016. This information is information that SynAct Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

ÅRSREDOVISNING - Spotlight Stock Market

Bolaget har utvecklat en Synact Pharma - idag är det sista teckningsdag via Nordnet och Avanza. Imorgon klockan 15:00 är deadline för teckning via teckningssedel. Info om Teckningskursen är 6,70 per ny aktie.

Årsredovisningen och koncernredovisningen för räkenskapsåret 2019 finns nu tillgänglig på bolagets webbplats (www.synactpharma.com), på Spotlight Stock Markets webbplats … The press release of March 31 stated that SynAct Pharma estimates that the cost of a clinical trial with AP1189 on Covid-19 patients will not exceed 15-20 million SEK. The company expects that today’s cash and an expected 32.8 million SEK from the redemption of subscription rights T0 2 July 2020 will fund the company through to important milestones in other projects. Stable Share Price: SYNACT is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: SYNACT's weekly volatility (9%) has been stable over the past year.
F ilb

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Learn about SYNACT (XSAT) with our data and independent analysis including price, star rating, valuation, dividends, and financials.
Uralstring medeltiden

schablonintakt fondandelar
yh utbildning vad är det
humanistisk teori personlighet
www student umu se registrering
jacques lepesqueur
klinisk farmakologisk afdeling auh
eu nya regler för garantipension utomlands

SynAct Pharma AB Skatteverket

Idag, den 18 november 2019, inleds teckningstiden i SynAct Pharma AB:s ("SynAct") företrädesemission av units för att öka det kommersiella värdet för AP1189 genom att slutföra fas II-studien inom reumatoid artrit, samt att uppnå Proof-of-Concept med AP1189 inom den nya indikationen nefrotiskt syndrom. Även allmänheten inbjuds att teckna SynAct Pharma's share has been listed on Spotlight Stock Market since 2016.